Biogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments. The Alzheimer’s treatment developer said Friday it will pay $172.50 in cash for each share ...
Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7.3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects into touch ...
Biogen’s growth strategy includes M&A deals and the drugmaker is making a big one with the $7.3 billion buyout of Reata Pharmaceuticals, a rare disease company whose main asset is the only ...
(Reuters) -Biogen agreed to buy rare disease drugmaker Reata Pharmaceuticals for nearly $6.5 billion, the first large acquisition under new CEO Christopher Viehbacher as he seeks to return the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results